FIGURE 4.
Long‐term retention rates during open‐label extension (OLE) studies. BRV, brivaracetam; CNB, cenobamate; LAC, lacosamide; LEV, levetiracetam; PER, perampanel
Long‐term retention rates during open‐label extension (OLE) studies. BRV, brivaracetam; CNB, cenobamate; LAC, lacosamide; LEV, levetiracetam; PER, perampanel